Are guidelines for anticoagulation useful in cancer patients?
|
|
- Leslie Crawford
- 5 years ago
- Views:
Transcription
1 Session 3 Striking a Balance Between Bleeding and the Risk of Thrombosis in Cancer Patients Are guidelines for anticoagulation useful in cancer patients? Sebastian Szmit Department of Pulmonary Circulation and Thromboembolic Diseases Head of Department: Prof. Adam Torbicki Department of Oncology Head of Department: Prof. Tadeusz Pieńkowski
2
3 OnCOReview International Journal for Interdisciplinary Oncology The Official Journal of East European Branch of International CardiOncology Society
4
5 Several national and international guidelines for the prevention and treatment of VTE in cancer patients have been published in the past
6 The latest guidelines were recently prepared by different globally recognised societies
7 When may guidelines be useful and helpful in cancer patients? 1) Which anticoagulants are the best choice in cancer patients? 2) What does secondary antithrombitic prevention mean? what is the optimal dose of heparin? how long should be continued? 3) What does primary antithrombitic prevention mean? during pharmacological anticancer therapy during surgery due to cancer 4) What is recommended in special situation? bleeding thrombocytopenia severe renal failure
8 Which anticoagulants are the best choice for acute VTE treatment in cancer patients? Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations LMWH is recommended for the initial treatment of established VTE in cancer patients [Grade 1B]. Fondaparinux and UFH can be also used for the initial treatment of established VTE in cancer patients [Grade 2D]. In patients with DVT of the leg / PE and cancer, we suggest LMWH over VKA therapy (Grade 2B). Choice of treatment in patients with and without cancer is sensitive to the individual patient s tolerance for daily injections, need for laboratory monitoring, and treatment costs. The standard initial treatment of an acute episode of VTE in cancer and non-cancer patients consists: LMWH s.c. at a dose adjusted to body weight: (e.g. dalteparin or enoxaparin) UFH - first administered as a bolus of 5000 IU, followed by continuous infusion adjusted to achieve and maintain an activated partial thromboplastin time (aptt) prolongation of times the basal value.
9 Can we use thrombolysis as effective and safety method for treatment of cancer patients with severe VTE? Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations Thrombolysis in cancer patients with established VTE may only be considered on a case-by-case basis, with specific attention paid to contraindications, especially bleeding risk (brain metastasis) [Best clinical practice] Not specified Thrombolytic treatment should be considered for specific subgroups of patients such as those with PE presenting with severe right ventricular dysfunction, and for patients with massive ilio-femoral thrombosis at risk for limb gangrene, where rapid venous decompression and flow restoration may be desirable. Urokinase, streptokinase and tissue-type plasminogen activator are able to achieve a rapid lysis of fresh pulmonary emboli [II, A].
10 What do guidelines say about new anticoagulant agents in cancer patients? Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations It was premature to issue recommendations on the use of new agents in this setting, because: -absence of specific data - none of the experts had enough clinical experience with their use In patients with DVT and cancer who are not treated with LMWH, we suggest VKA over dabigatran or rivaroxaban for long-term therapy (Grade 2B). In patients with PE and cancer who are not treated with LMWH, we suggest VKA over dabigatran or rivaroxaban for long-term therapy (Grade 2C). Not specified
11 Clinical trials with new parenteral indirect FXa anticoagulants for prophylaxis and treatment of venous thromboembolism Clinical trial Subjects (n) Cancer (%) Drug Conclusions SAVE-ONCO % Semuloparin Prophylaxis SAVE-ABDO % Semuloparin prophylaxis Van Gogh-DVT Van Gogh-PE Van-Gogh extension % % % Idraparinux Idraparinux Idraparinux SEM superior to placebo Noninferiority of SEM versus ENO IDRA noninferior to heparin + VKA IDRA inferior to heparin + VKA IDRA superior to placebo EQUINOX (DVT) % Idrabiotaparinux Non significant CASSIOPEA (PE) % Idrabiotaparinux ENO + IDRAB noninferior to ENO + VKA
12 Evidence regarding treatment of cancer-related VTE with the new oral anticoagulants is limited: Clinical trial Subjects (n) Cancer (%) Drug Conclusions EINSTEIN-DVT EINSTEIN-PE EINSTEIN- EXTENSION AMPLIFY-EXT % % % % Rivaroxaban RIV noninferior to ENO + WRF Rivaroxaban RIV noninferior to ENO + WRF Rivaroxaban Apixaban RIV superior to placebo API (both doses) superior to placebo RE-COVER % Dabigatran DAB noninferior to WRF RE-MEDY % Dabigatran DAB noninferior to WRF RE-SONATE 1343 < 1% Dabigatran DAB superior to placebo
13 Pooled analysis of recurrent venous thromboembolism and clinically relevant bleeding in patients with cancer included in the EINSTEIN-DVT and EINSTEIN-PE studies. Rivaroxaban seems to be effective and safe in cancer patients with VTE Vascular Health and Risk Management 2013:9
14 New anticoagulants seem to be very atractive but In my opinion we know too little about their Interactions with anticancer drugs activity (risk of cancer progression) Influence on cancer cells survival (risk of cancer progression) Vascular Health and Risk Management 2013:9
15 When may guidelines be useful and helpful in cancer patients? 1) Which anticoagulants are the best choice in cancer patients? 2) What does secondary antithrombotic prevention mean? what is the optimal dose of heparin? how long should be continued? 3) What does primary antithrombitic prevention mean? during pharmacological anticancer therapy during surgery due to cancer 4) What is recommended in special situation? bleeding thrombocytopenia severe renal failure
16 LMWH used in studies comparing early maintenance treatment (10 days to 3 months) and long-term (beyond 3 months) treatment It was only comparison between LMWH alone and short-term heparin followed by VKA LMWH dosage duration study Enoxaparin 1.5 mg / kg / day for 3 months CANTHANOX [MEYER 2002] Dalteparin 200 IU / kg / day 150 IU / kg / day for 1 month for 5 months CLOT [LEE 2003] Tinzaparin 175 IU / kg / day for 3 months LITE [HULL 2006] no head-to-head comparison between different doses of LMWH no study comparing 3 vs. 6 months of LMWH clinical trials have not been specifically designed to evaluate the duration of anticoagulation
17 What do guidelines say about long-term treatment of VTE in cancer patients? We can find the indication for a minimum of 3 months and information that the period of 6 months seem to be more effective Guidelines International consensus (2013) Recommendations LMWH should be used for a minimum of 3 months to treat established VTE in cancer patients; however, patients were treated for 6 months in the largest study in this setting [Grade 1A]. After 3 6 months, termination or continuation of anticoagulation (LMWH or VKA) should be based on individual evaluation of the benefit-risk ratio, tolerability, patients preference and cancer activity [Best clinical practice]. American College of Chest Physicians (2012) European Society of Medical Oncology (2011) In patients with DVT/PE and active cancer, if there is a low or moderate bleeding risk, we recommend extended anticoagulant therapy over 3 months of therapy (Grade 1B), and if there is a high bleeding risk, we suggest extended anticoagulant therapy (Grade 2B). Long-term treatment for 6 months with 75 80% (i.e. 150 U/kg once daily) of the initial dose of LMWH is safe and more effective than treatment with a VKA. This schedule is recommended [I, A].
18 But active cancer is a major risk factor for recurrence of VTE, the rate of recurrence being approximately 20% during the first 12 months after the first event Joung S, Robinson B. N Z Med J 2002;115(1155): Hutten BA et al. J Clin Oncol 2000;18(17): Can we understand cancer patients as candidates for indefinite anticoagulant treatment after a first episode of VTE?
19 What is the optimal duration of anticoagulant therapy in patients with cancerrelated deep vein thrombosis? Results of the Cancer-DACUS Study 409 patients with active cancer and a first episode of DVT received LMWH for 6 months and were then divided into three groups on the basis of the results of a duplex ultrasound examination Group Clinical decision Rates of VTE recurrence A1: with residual venous thrombosis A2: with residual venous thrombosis B: without residual venous thrombosis randomized to continuation of anticoagulation randomized to discontinuation of anticoagulation recommendation to discontinue anticoagulant therapy Rates of major bleeding 14.2% 4.2% p = % 1.6% p < % 1.9% After 6 months of treatment with LMWH, patients with active cancer and residual venous thrombosis may have better prognosis if they continue anticoagulation Siragusa S et al. Blood 2010; 116: 190.
20 In my opinion: For patients with PE and cancer, LMWH should be considered for the first 3 to 6 months. After this period, anticoagulant therapy with VKA or LMWH, or with a new oral anticoagulant, should be continued indefinitely, or until the cancer is considered active.
21 The decisions regarding chronic anticoagulation should be made on a case-by case basis after considering the success of anticancer therapy, the estimated risk of VTE recurrence, the bleeding risk, the preference of the patient. Periodic reassessment of the risk benefit ratio of chronic anticoagulant treatment should be recommended.
22 What do guidelines say about treatment of VTE recurrence in cancer patients under anticoagulation? Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations Three options can be considered: (i) switch from VKA to LMWH in patients treated with VKA; (ii) increase in LMWH dose in patients treated with LMWH, (iii) vena cava filter insertion [Best clinical practice] Not specified on long-term anticoagulation with VKA: A. INR is in the subtherapeutic range achieve a stable INR between 2.0 and 3.0. B. INR is in the therapeutic range there are two options: (i) shift to another method of anticoagulation, (ii) increase the INR to a target of 3.5 while receiving a reduced dose of LMWH escalating the dose [II, B]
23 In my opinion: Patients adequately anticoagulated who develop VTE recurrence should be checked for progression of their malignancy. We do not find such indication in guidelines
24 When may guidelines be useful and helpful in cancer patients? 1) Which anticoagulants are the best choice in cancer patients? 2) What does secondary antithrombitic prevention mean? what is the optimal dose of heparin? how long should be continued? 3) What does primary antithrombitic prevention mean? during pharmacological anticancer therapy during surgery due to cancer 4) What is recommended in special situation? bleeding thrombocytopenia severe renal failure
25 What should we understand as primary trombophylaxis of VTE in hospitalized cancer patients? Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations We recommend prophylaxis with LMWH, UFH or fondaparinux in hospitalized medical patients with cancer and reduced mobility [Grade 1B]. For acutely ill hospitalized medical patients at increased risk of thrombosis, we recommend anticoagulant thromboprophylaxis with low molecularweight heparin [LMWH], low-dose unfractionated heparin (LDUH) bid, LDUH tid, or fondaparinux (Grade 1B). Prophylaxis with UFH, LMWH or fondaparinux in hospitalized cancer patients confined to bed with an acute medical complication is recommended [I, A].
26 In choosing the specific anticoagulant drug to be used for pharmacoprophylaxis, choices should be based on 1) patient preference, 2) compliance, 3) ease of administration (eg, daily vs bid vs tid dosing), 4) costs
27 How to understand the recommendations in ambulatory medical cancer patients treated with chemotherapy? There are several conflicting indications Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations In patients receiving chemotherapy, prophylaxis is not recommended routinely [Grade 1B]. Primary pharmacological prophylaxis of VTE may be indicated in patients with locally advanced or metastatic pancreatic cancer treated with chemotherapy and having a low bleeding risk [Grade 1B]. Primary pharmacological prophylaxis of VTE may be indicated in patients with locally advanced or metastatic lung cancer treated with chemotherapy and having a low bleeding risk [Grade 2B]. In outpatients with cancer who have no additional risk factors for VTE, we suggest against routine prophylaxis with LMWH or LDUH (Grade 2B) and recommend against the prophylactic use of vitamin K antagonists (Grade 1B)
28 In outpatients with solid tumors who have additional risk factors for VTE and who are at low risk of bleeding, we suggest prophylactic dose LMWH or LDUH over no prophylaxis (Grade 2B) Remarks: Additional risk factors for venous thrombosis in cancer outpatients include: previous venous thrombosis, immobilization, hormonal therapy, angiogenesis inhibitors, thalidomide and lenalidomide. CHEST 2012; 141(2)(Suppl):e195S e226s
29 In outpatients with solid tumors who have additional risk factors for VTE and who are at low risk of bleeding, we suggest prophylactic dose LMWH or LDUH over no prophylaxis (Grade 2B) Remarks: And it may be understood as: patients with bone matastases and low activity ( immobilization ), patients treated with tamoxifen or aromatase inhibitors patients treated with bevacizumab or sunitinib / pazopanib or other TKI..should receive trombophylaxis.??????? CHEST 2012; 141(2)(Suppl):e195S e226s
30 How to understand the recommendations in ambulatory medical cancer patients treated with chemotherapy? There are several conflicting indications Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations In patients receiving chemotherapy, prophylaxis is not recommended routinely [Grade 1B]. Primary pharmacological prophylaxis of VTE may be indicated in patients with locally advanced or metastatic pancreatic cancer treated with chemotherapy and having a low bleeding risk [Grade 1B]. Primary pharmacological prophylaxis of VTE may be indicated in patients with locally advanced or metastatic lung cancer treated with chemotherapy and having a low bleeding risk [Grade 2B]. In outpatients with cancer who have no additional risk factors for VTE, we suggest against routine prophylaxis with LMWH or LDUH (Grade 2B) and recommend against the prophylactic use of vitamin K antagonists (Grade 1B) Prophylaxis in cancer patients receiving adjuvant chemotherapy and/or hormone therapy is not recommended [I, A]. Extensive, routine prophylaxis for advanced cancer patients receiving chemotherapy is not recommended, but may be considered in high-risk ambulatory cancer patients [II, C].
31 Predictive model for chemotherapy-associated VTE in ambulatory cancer patients. This model might be used to identify ambulatory cancer patients who are clinically at high risk for VTE (II, B). The rates of VTE: low-risk category - 0,5% (score = 0) intermediate-risk category 2% (score = 1 2); high-risk category - 7% (score 3)
32 There is no evidence to recommend the use of anticoagulation to influence prognosis of cancer [I, B].
33 Although there are published data that some patients may achieve better overall survival within primary trombophylaxis and palliative chemotherapy Autor n heparin duration effect Lebeau 277 UFH 5 weeks 317 days vs. 261 days; p = 0.01 Kakkar FAMOUS 385 dalteparin 52 weeks or until death 44 months vs. 24 months; p = 0.03 Altinbas 84 dalteparin 18 weeks 13 months vs. 8 months; p = 0.01 Klerk MALT 302 nadroparin 6 weeks 8 months vs. 6.6 months; p = 0.02 Sideras 138 dalteparin 104 weeks or until death No significant effect on median survival Blood Reviews 23 (2009)
34 What is recommended in ptients treated with thalidomide or lenalidomide? Guidelines International consensus (2013) American College of Chest Physicians (2012) Recommendations In patients treated with IMiDs combined with steroids and/ or chemotherapy (doxorubicin), VTE prophylaxis is recommended: VKA at low or therapeutic doses, LMWH at prophylactic doses low-dose aspirin The efficacy of these regimens remains unclear [Grade 2C]. who have additional risk factors for VTE and who are at low risk of bleeding, we suggest prophylacticdose LMWH or LDUH over no prophylaxis (Grade 2B) thalidomide and lenalidomide on the list of additional risk factors European Society of Medical Oncology (2011) Consider LMWH, aspirin or adjusted-dose warfarin (INR=1.5) in myeloma patients receiving thalidomide plus dexamethasone or thalidomide plus chemotherapy [II, B].
35 When may guidelines be useful and helpful in cancer patients? 1) Which anticoagulants are the best choice in cancer patients? 2) What does secondary antithrombitic prevention mean? what is the optimal dose of heparin? how long should be continued? 3) What does primary antithrombitic prevention mean? during pharmacological anticancer therapy during surgery due to cancer 4) What is recommended in special situation? bleeding thrombocytopenia severe renal failure
36 Guidelines recommend primary pharmacoprophylaxis in all surgical cancer patients? The efficacy of prophylaxis is unquestionable Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations Use of LMWH once a day or a low dose of UFH three times a day is recommended to prevent postoperative VTE in cancer patients; pharmacological prophylaxis should be started 12 2 h preoperatively and continued for at least 7 10 days; there are no data allowing conclusions regarding the superiority of one type of LMWH over another [Grade 1A]. Use of the highest prophylactic dose of LMWH to prevent postoperative VTE in cancer patients is recommended [Grade 1A]. There is no evidence to support fondaparinux as an alternative to LMWH for the prophylaxis of postoperative VTE in cancer patients [Grade 2C]. Pharmacoprophylaxis of VTE in surgical cancer patients is recommended In surgical cancer patients, high dose s.c. LMWH (e.g. enoxaparin 4000 U of anti-xa activity, dalteparin 5000 U of anti-xa activity) once daily, or s.c.ufh 5000 U (three times daily) are recommended [I, A]. The role of prophylaxis is unquestionable (I, A).
37 But what do guidelines say about extended duration of prophylaxis in high risk surgical cancer patients? The proposed extended prophylaxis means only 4 weeks!!! Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations Extended prophylaxis (4 weeks) to prevent postoperative VTE after major laparotomy in cancer patients may be indicated in patients with a high VTE risk and low bleeding risk [Grade 2B]. For high-vte-risk patients undergoing abdominal or pelvic surgery for cancer who are not otherwise at high risk for major bleeding complications, we recommend extended-duration pharmacologic prophylaxis (4 weeks) with LMWH over limited-duration prophylaxis (Grade 1B). Cancer patients undergoing elective major abdominal or pelvic surgery should receive in hospital and post-discharge prophylaxis with s.c. LMWH for up to 1 month after surgery [I, A].
38 Relative risk of venous thromboembolism by time since inpatient surgery and by surgery type Six weeks after surgery 7-12 weeks after surgery 4-12 months after surgery 1 year after surgery Cancer 91.6 (73.9 to 113.4) 53.4 (40.0 to 71.4) 34.4 (29.3 to 40.2) 6.1 (4.9 to 7.6) Hip or knee replacement (187.8 to 259.2) 39.7 (27.3 to 57.8) 4.6 (2.9 to 7.2) 2.7 (1.9 to 4.0) Fracture 89.0 (65.5 to 121.0) 39.8 (25.0 to 63.4) 2.9 (1.5 to 5.9) 0.6 (0.3 to 1.5) All other surgery 36.0 (29.6 to 43.8) 8.4 (5.6 to 12.6) 3.7 (2.9 to 4.8) 1.7 (1.4 to 2.0) The recommended extended duration of tromboprophylaxis in surgical cancer patients seems to be too short!!! Sweetland S, BMJ 2009;339:b4583.
39 When may guidelines be useful and helpful in cancer patients? 1) Which anticoagulants are the best choice in cancer patients? 2) What does secondary antithrombitic prevention mean? what is the optimal dose of heparin? how long should be continued? 3) What does primary antithrombitic prevention mean? during pharmacological anticancer therapy during surgery due to cancer 4) What is recommended in special situation? bleeding thrombocytopenia severe renal failure
40 Which anticoagulants are the best choice in cancer patients? Prophylaxis of VTE & severe renal faulire Guidelines International consensus (2013) American College of Chest Physicians (2012) Recommendations In the presence of severe renal failure (creatinine clearance < 30 ml /min.) we suggest using UFH followed by early VKA (possible from day 1) or LMWH adjusted to anti-xa level for the treatment of established VTE [Best clinical Practice] For patients receiving therapeutic LMWH who have severe renal insufficiency (calculated creatinine clearance, 30 ml/min), we suggest a reduction of the dose rather than using standard doses (Grade 2C). LMWH and fondaparinux are retained in patients with renal impairment, whereas this is not a concern with UFH European Society of Medical Oncology (2011) In patients with severe renal failure (creatinine clearance <25 30 ml), UFH i.v. or LMWH with anti-xa activity monitoring is recommended [I, A].
41 Which anticoagulants are the best choice in cancer patients? Prophylaxis of VTE & bleeding Guidelines International consensus (2013) American College of Chest Physicians (2012) European Society of Medical Oncology (2011) Recommendations LMWH may increase the bleeding risk, particularly in the context of thrombocytopenia For acutely ill hospitalized medical patients at increased risk of thrombosis who are bleeding or at high risk for major bleeding, we suggest the optimal use of mechanical thromboprophylaxis with graduated compression stockings (GCS) (Grade 2C) or intermittent pneumatic compression (IPC) (Grade 2C) For high-vte-risk general and abdominalpelvic surgery patients who are at high risk for major bleeding complications or those in whom the consequences of bleeding are thought to be particularly severe, we suggest use of mechanical prophylaxis, preferably with IPC, over no prophylaxis until the risk of bleeding diminishes and pharmacologic prophylaxis may be initiated (Grade 2C). The use of an inferior vena cava filter should be considered in patients with recurrent PE despite adequate anticoagulant treatment or with a contraindication to anticoagulant therapy (i.e. active bleeding and profound, prolonged thrombocytopenia) Once the risk of bleeding is reduced, patients with a vena cava filter should receive or resume anticoagulant therapy in order to reduce the risk of recurrent deep vein thrombosis of the lower extremities [II, A].
42 In cancer patients with thrombocytopenia, full doses of anticoagulant can be used for the treatment of established VTE if the platelet count is > 50 G/L and there is no evidence of bleeding; for patients with a platelet count below 50 G/L, decisions on treatment and dosage should be made on a case-by-case basis with the utmost caution [Best clinical practice] In cancer patients with mild thrombocytopenia if platelet count > 80 G/L pharmacological prophylaxis may be used; if the platelet count is below 80 G/L, pharmacological prophylaxis may only be considered on a case-by-case basis and careful monitoring is recommended [Best clinical practice]
43 Are guidelines for anticoagulation useful in cancer patients? Advantages of guidelines Conclusions Disadvantages of guidelines Strong recommendation for LMWH over VKA therapy No recommendations on the use of new anticoagulants Strong recommendation for > 3 months treatment of established VTE with LMWH Strong recommendation for primary trombophylaxis in surgical cancer patients Strong recommendation for primary trombophylaxis in HOSPITALIZED cancer patients Recommendation on extended secondary trombophylaxis after first 6 months IS NOT clear Primary trombophylaxis in high risk surgical patients should probably be more extended than currently recommended There is no good definition of patients receiving palliative anticancer treatment and requaring primary thrombophylaxis for better outcome
DEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationPatients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the 1 ability of tumour cells to activate
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationCPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2015 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationCANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationincidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2
CANCER ASSOCIATED THROMBOSIS TREATMENT Patients with cancer are at a greater risk of developing venous thromboembolism than non-cancer patients, partly due to the ability of tumour cells to activate the
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationCancer and Thrombosis
Cancer and Thrombosis The close relationship between venous thromboembolism and cancer has been known since at least the 19th century by Armand Trousseau. Thrombosis is a major cause of morbidity and mortality
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationPRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES
PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES Mario Mandalà, MD Unit of Clinical Research Department of Oncology and Haematology Papa Giovanni XXIII Hospital Cancer Center
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationIn the Clinic: Annals Sweta Kakaraparthi 1/23/15
In the Clinic: Annals Sweta Kakaraparthi 1/23/15 Case Scenerio 56 year old female with breast cancer presents to the clinic for her 3 month followup! She is concerned about blood clots and asks you about
More informationVenous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2012) NICE guideline CG144 Appendix A: Summary of new evidence from Summary of evidence from previous year Diagnosis Diagnostic
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationPrevention and management of venous thromboembolism M. AAPRO
Prevention and management of venous thromboembolism M. AAPRO Thromboprophylaxisof DVT and PE in AmbulatoryCancerPatients Zurich, February 2017 M. AAPRO Based on a lesson in April 2016 by M. DICATO M.D.,
More informationVenous Thromboembolism (VTE) in Myeloma. Christine Chen May 2017
Venous Thromboembolism (VTE) in Myeloma Christine Chen May 2017 Objectives 1. Review the magnitude of the problem and why myeloma patients are at risk of VTE 2. Discuss thromboprophylaxis approaches in
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationNon commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background
Italian Journal of Medicine 2013; volume 7(s8):29-35 The treatment of venous thromboembolism with new oral anticoagulants Davide Imberti AUSL Piacenza, Italy ABSTRACT Traditional anticoagulants, such as
More informationEpidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
More informationTHROMBOSIS RISK FACTOR ASSESSMENT
Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)
More informationCancer and the Heparins
Cancer and the Heparins Wim P Ceelen, MD, PhD, FACS Department of GI Surgery - UZ Gent Senior Clinical Researcher - FWO Overview Mechanisms of cancer induced thrombosis Guidelines for prevention and treatment
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationThis chapter will describe the effectiveness of antithrombotic
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
More informationDVT - initial management NSCCG
Background information Information resources for patients and carers Updates to this care map Synonyms Below knee DVT and bleeding risks Patient with confirmed DVT Scan confirms superficial thrombophlebitis
More informationCancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationWith All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis
BRIGHAM AND WOMEN S HOSPITAL With All the New Drugs, This is How I Treat Acute DVT and Superficial Phlebitis Gregory Piazza, MD, MS Division of Cardiovascular Medicine Brigham and Women s Hospital April
More informationLa terapia del TEV nel paziente oncologico nell'era dei DOAC
XXVI CONGRESSO NAZIONALE FCSA Bologna, 5-7 Novembre 2015 Tromboembolismo venoso La terapia del TEV nel paziente oncologico nell'era dei DOAC ANNA FALANGA Immunoematologia e Medicina Trasfusionale e Centro
More informationTHROMBOPROPHYLAXIS IN CANCER PATIENTS
CANCER ASSOCIATED THROMBOSIS THROMBOPROPHYLAXIS IN CANCER PATIENTS Cancer is an important risk factor for venous thromboembolism (VTE). Research has shown that 4-20% of 1 patients with cancer experience
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationJ Clin Oncol 31: by American Society of Clinical Oncology INTRODUCTION
VOLUME 31 NUMBER 17 JUNE 10 2013 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E Gary H. Lyman, Nicole M. Kuderer, and Jeffrey M. Clarke, Duke University and Duke Cancer Institute, Durham;
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationLow Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders
SURGICAL GRAND ROUNDS March 17 th, 2007 Low Molecular Weight Heparin for Prevention and Treatment of Venous Thromboembolic Disorders Guillermo Escobar, M.D. LMWH vs UFH Jayer s sales pitch: FALSE LMW is
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationNew Oral Anticoagulants Prevention and Treatment of DVT and PE
New Oral Anticoagulants Prevention and Treatment of DVT and PE Grigoris T Gerotziafas Groupe de Thrombose Equipe de recherche ER2UPMC Interactions cellulaires tumorales et leur environnement et réponses
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationPostsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Clinical Position Statement Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Effective: October 2017 Next Review: September 2018 CLINICAL POSITION STATEMENT Postsurgical
More informationNew oral anticoagulants and Palliative Care.
New oral anticoagulants and Palliative Care. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationAspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial Wednesday, June 6, 2018, 2:00PM ET Guest Author: David R. Anderson, MD Presenter: Sara Vazquez, PharmD Moderators:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationBenefit risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism
Review Article 231 Benefitrisk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism Jan Beyer-Westendorf 1 ; Walter Ageno 2 1 Center for Vascular Diseases
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationSpontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren
Spontane und Tumor-assoziierte VTE: womit wie lange antikoagulieren Paul Kyrle Allgemeines Krankenhaus Wien Disclosures relevant for this presentation Consultancies, member of advisory boards, speaker
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationPrevention and treatment of venous thromboembolic disease
REVIEW Prevention and treatment of venous thromboembolic disease SUSAN McNEILL AND CATHERINE BAGOT Awareness of the risk factors for venous thromboembolic (VTE) disease and timely administration of thromboprophylaxis
More informationGLIOMA - VENOUS THROMBOEMBOLISM. Miguel Navarro. Hospital Universitario de Salamanca-IBSAL
GLIOMA - VENOUS THROMBOEMBOLISM Miguel Navarro. Hospital Universitario de Salamanca-IBSAL GLIOMA - VTE GLIOMA - VTE The two string problem Substantial risk for developing VTE Concern antithrombotic agents
More informationAdam Goldfarb, M.A., D.C., D.E.S.S. Introduction
Venous Thromboembolism Prophylaxis following Lower Extremity Orthopedic Surgery: A Review of the Biomedical Research Literature and Evidence-Based Policy in the United States. Adam Goldfarb, M.A., D.C.,
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationACCP CLINICAL RESOURCE
ACCP CLINICAL RESOURCE Facilitating Learning and Change in Clinical Care Antithrombotic Therapy and Prevention of Thrombosis 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice
More informationReview Guideline recommendations for the treatment of established VTE Initial treatment (fi rst 10 days) Panel 1:
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer Dominique Farge, Henri Bounameaux,
More informationManagement of Cancer Associated VTE
Management of Cancer Associated VTE Jean M. Connors, MD 2017 Master Class Course Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine HMS
More informationIs Oral Rivaroxaban Safe and Effective in the Treatment of Patients with Symptomatic DVT?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 1-1-2013 Is Oral Rivaroxaban Safe and Effective
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationNovel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology
Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationChoosing and Managing Direct Oral Anticoagulants (DOACs)
Choosing and Managing Direct Oral Anticoagulants (DOACs) Ana G. Antun, MD, MSc Assistant Professor, Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University 1 Outline
More informationVenous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
More informationNew antithrombotic agents in the treatment of VTE; a subgroup analysis of the Phase III randomized clinical trials.
Interactions cellulaires tumorales et leur environnement et réponses aux agents anticancéreux. New antithrombotic agents in the treatment of VTE; a subgroup analysis of the Phase III randomized clinical
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationIndividualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationThese are guidelines only and can be deviated from if it is thought to be in the patient s best interest.
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationTransitions of care in anticoagulated patients
Journal of Multidisciplinary Healthcare open access to scientific and medical research Open Access Full Text Article Transitions of care in anticoagulated patients Expert Opinion Franklin Michota Department
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationCancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School
Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer
More information